Moderna mini-dose rouses big response
Two jabs that each contained only one-quarter of the standard dose of Moderna’s COVID-19 vaccine gave rise to long-lasting protective antibodies and virus-fighting T cells. Researchers analysed the immune responses of 35 people who received the smaller dose as part of the earliest trial of the messenger-RNA-based vaccine. Their levels of both antibodies and T cells were comparable to those in people who have recovered from COVID-19. The results hint at the possibility of administering fractional doses to stretch limited vaccine supplies and accelerate the global immunization effort.
Nature | 4 min read
Reference: medRxiv preprint